Carrington Laboratories, Inc.
Medical Devices & Tech
2001 Walnut Hill Lane
Irving, TX 75038 USA
phone: 972.518.1300
fax: 972-518-1020
Symbol CARN
Exchange Nasdaq
Founded 1986
Employees
www.carringtonlabs.com
Research Sector Medical Devices & Tech
Summary Description
Therapeutics for ulcerative colitis, cancer as well as wound management.
Management
Dr. Carlton E. Turner, President and CEO; Robert W. Schnitzius, CFO; Doug Golwas, VP Corporate Sales and Marketing
Ownership
Financials


* numbers in thousands

Recent Results
For the 12 months ended 12/31/05, the company reported revenue of $28 million with a net loss of $5.3 million. For the year 2004, the company reported revenue of $30.8 million and a net profit of $36,000.
 
Keywords
woundwound, woundcare

Comment | Printable Version | Oct. 01, 2008
If you work for Carrington Laboratories, Inc. and want to update this profile, click here

Description
Carrington Laboratories, Inc. is a research-based biopharmaceutical, medical device, raw materials and nutraceutical company engaged in the development, manufacturing and marketing of naturally derived complex carbohydrates and other natural product therapeutics for the treatment of illnesses & wounds.
Products / Services
Retail Products, Wound Care for Medical Professionals, Raw Materials, Specialty Manufacturing & Assembly, Drug Delivery Technology, Diabetic Care products, Radiation Care,
Market / Customers
Carrington is a full-service manufacturer of patented raw materials from Aloe vera L., nutraceuticals, cosmetics, hydrogels and over-the-counter monograph drug products for the consumer and medical products sectors.
Competitors / Substitutes / Alternatives
Carrington's main competitors are Bristol-Myers Squibb Co. and Johnson & Johnson.
Strategy
Carrington's strategy is to continue to fund DelSite as it pursues the nasal delivery system for therapeutics and vaccines for influenza, particularly the bird flu strain. They will also continue to seek out strategic partnerships and collaboration arrangements related to their GelSite® and GelVac(tm) platform technologies. They intend to continue to expand and diversify their customer base and continue to develop and offer new products and extensions of existing product lines.


2008-10-10-469